Myriad Genetics Inc (NASDAQ:MYGN)
| 27.84 Delayed Data As of 4:00pm ET |  -0.60 / -2.11%Today’s Change | 9.24 Today|||52-Week Range 31.60 | +40.78% Year-to-Date |
Latest MYGN News | Press Releases
| Myriad Genetics (MYGN) Collaborates to Advance Oncology Care 10:03am / Zacks.com - Paid Partner Content | Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript Feb 23 / MotleyFool.com - Paid Partner Content |
| Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line Feb 24 / Zacks.com - Paid Partner Content | Myriad Genetics (MYGN) Reports Q2 Loss, Tops Revenue Estimates Feb 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 28.44 |
| Today’s open | 28.24 |
| Day’s range | 26.79 - 28.45 |
| Volume | 42,900 |
| Average volume (3 months) | 803,157 |
| Market cap | $2.3B |
Data as of 4:00pm ET, 03/05/2021
Growth & Valuation
| Earnings growth (last year) | -4,389.30% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +6.00% |
| Revenue growth (last year) | -24.97% |
| P/E ratio | NM |
| Price/Sales | 1.32 |
| Price/Book | 2.48 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LNTHLantheus Holdings In... | +0.60 | +3.25% |
| VCYTVeracyte Inc | +0.73 | +1.56% |
| TRILTrillium Therapeutic... | -0.19 | -1.86% |
| CLDXCelldex Therapeutics... | +1.07 | +4.25% |
Data as of 4:00pm ET, 03/05/2021
Financials
| Next reporting date | November 9, 2021 |
| EPS forecast (this quarter) | -$0.16 |
| Annual revenue (last year) | $638.6M |
| Annual profit (last year) | -$199.5M |
| Net profit margin | -31.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
